Biopharma's Investment in Novel Targets Analysis

This technical report by L.E.K. Consulting examines the current state of biopharma investment in novel biological targets. It outlines the significant concentration of drug development around a limited number of established targets, with approximately 13,600 unique drug-target pairs identified in the R&D pipeline. The report highlights a concerning trend where the annual entry of novel targets has sharply declined from around 100 to just 30 in 2024, despite an overall increase in the R&D pipeline size. The analysis indicates that while there is active R&D in key therapeutic areas such as oncology and immunology, there remains a critical need for investment in underexplored targets. The report also discusses the strategic implications of this trend for future pipeline planning, emphasizing the necessity for the biopharma industry to rebalance its investment priorities to enhance clinical outcomes and foster innovation in therapeutic development.